6.3.2.12	analysis	a simple radioassay for dihydrofolate synthetase activity and its application to an inhibition study of new pteroate analogs	
6.3.2.12	biotechnology	production of active dihidrofolate synthase in milligram scale	
6.3.2.12	drug development	enzyme dihydrofolate synthase is a target for development of specific drugs against infections with the human pathogen Pneumocystis jirovecii that can cause pneumonia	
6.3.2.12	medicine	study on therapeutic efficacy of sulfadoxine-pyrimethamine at two locations in the Peruvian Amazon in order to correlate the presence of polymorphisms in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase to in vitro parasite susceptibility to sulfadoxine and pyrimethamine and to in vivo treatment outcomes. A single mutation present in the isolate obtained at the time of enrollment from either dihydrofolate reductase, 164L, or dihydropteroate synthase, 540E, predicts treatment failure as well as any other single gene alone or in combination. Patients carrying parasites with the dihydrofolate reductase 164L mutation are 3.6times as likely to be treatment failures while patients carrying parasites with the dihydropteroate synthase 540E mutation are 2.6times as likely to fail treatment. Patients with both dihydrofolate reductase 164L and dihydropteroate synthase 540E mutations are 4.1times as likely to be treatment failures compared to patients having both wild forms I164 and K540	
6.3.2.12	medicine	target for antimalarial therapy